drugset / Trial / NCT03403309

Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial

NCT03403309 ↗

Phase 2 Completed 43 enrolled Yonsei University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A purpose of the present study is to investigate the capability of serum uric acid elevation, safety, and tolerability of inosine 5'-monophosphate in patients with multiple system atrophy with multicenter, randomized, placebo controlled, parallel assigned design. This may provide the cornerstone for future extended trial in multiple system atrophy, a debilitating disease to date.

Timeline

Start
2018-05-02
Primary completion
2019-06-10
Completion
2019-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Inosine 5'-monophosphate Unknown 1000 mg —